Illuminating Breast Cancer Recurrence Risk  |   > Search     |   Take me to: Oncotype - Home Healthcare Professionals - Home Oncotype DX Logistics - Home About Oncotype DX About Recurrence Oncotype DX Development Health Insurance Coverage Frequently Asked Questions Glossary Helpful Links About Oncotype DX What is Oncotype DX? Who is Oncotype DX For? How is Oncotype DX Performed? How Can Oncotype DX Benefit Me? Oncotype DX Results How Do I Get a Test? About Recurrence Oncotype DX Development Health Insurance Coverage Frequently Asked Questions Glossary Helpful Links Who is Oncotype DX For? The Oncotype DX® test was developed for women recently diagnosed with Stage I or II, node-negative, and estrogen receptor positive breast cancer. For these women it provides information on the likelihood that their individual cancer will return as well as how likely they are to benefit from the addition of chemotherapy to hormonal therapy. A recent study has also shown that Oncotype DX may be informative for post-menopausal women who are recently diagnosed with node-positive, hormone receptor-positive breast cancer. Because Oncotype DX was specifically tested in stage I and stage II breast cancer, it is not appropriate for use in women with in situ (ductal carcinoma, lobular carcinoma or pre-cancerous) or late stage (metastatic) breast cancer. If you have questions about your cancer stage, estrogen receptor status or lymph node status of your tumor, please check with your authorized healthcare provider. What's New? November 11, 2008 Genomic Health to Present at Stephens Fall Investment Conference November 10, 2008 Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated

© 2008 Genomic Health, Inc.  All rights reserved. | Home | Contact Us | Privacy | Terms and Conditions |